| Garhett J Ulmer, NP | |
|
6140 W Curtisian Ave Ste 200, Boise, ID 83704-0107 | |
| (208) 302-0000 | |
| Not Available |
| Full Name | Garhett J Ulmer |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 6140 W Curtisian Ave Ste 200, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619562295 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0001X | Internal Medicine - Clinical Cardiac Electrophysiology | 55923 (Idaho) | Secondary |
| 363L00000X | Nurse Practitioner | 55923 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Alphonsus Regional Medical Center | Boise, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Alphonsus Regional Medical Center Inc | 3476462359 | 509 |
News Archive
Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
To remove financial barriers associated with administration of the H1N1 vaccine and to encourage members to seek vaccination, Regence BlueCross BlueShield will provide coverage for the costs associated with the administration of the H1N1 vaccine during the 2009-2010 flu season, waiving co-pays and deductibles for all members covered by its insured plans. Regence will strongly encourage self-insured employers to cover the full cost to ensure that the greatest number of people are protected.
Internal Medicine Physician Rahul Deepankar, M.D. and Pediatrician Jane Kapral, M.D. are the two newest team members to join the Riverside Medical Center - West Campus in Coal City.
COVID-19 test results are now being automatically sent to GP systems as well as being communicated to the individual, giving GPs visibility of which of their patients have had COVID-19 tests and whether they have tested positive or negative.
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its supplemental Abbreviated New Drug Application (ANDA) for Phentermine HCl Capsules, 15 mg.
› Verified 9 days ago
| Entity Name | Saint Alphonsus Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649357716 PECOS PAC ID: 3476462359 Enrollment ID: O20040204001036 |
News Archive
Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
To remove financial barriers associated with administration of the H1N1 vaccine and to encourage members to seek vaccination, Regence BlueCross BlueShield will provide coverage for the costs associated with the administration of the H1N1 vaccine during the 2009-2010 flu season, waiving co-pays and deductibles for all members covered by its insured plans. Regence will strongly encourage self-insured employers to cover the full cost to ensure that the greatest number of people are protected.
Internal Medicine Physician Rahul Deepankar, M.D. and Pediatrician Jane Kapral, M.D. are the two newest team members to join the Riverside Medical Center - West Campus in Coal City.
COVID-19 test results are now being automatically sent to GP systems as well as being communicated to the individual, giving GPs visibility of which of their patients have had COVID-19 tests and whether they have tested positive or negative.
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its supplemental Abbreviated New Drug Application (ANDA) for Phentermine HCl Capsules, 15 mg.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Garhett J Ulmer, NP Po Box 381, Kooskia, ID 83539-0381 Ph: (208) 935-5073 | Garhett J Ulmer, NP 6140 W Curtisian Ave Ste 200, Boise, ID 83704-0107 Ph: (208) 302-0000 |
News Archive
Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
To remove financial barriers associated with administration of the H1N1 vaccine and to encourage members to seek vaccination, Regence BlueCross BlueShield will provide coverage for the costs associated with the administration of the H1N1 vaccine during the 2009-2010 flu season, waiving co-pays and deductibles for all members covered by its insured plans. Regence will strongly encourage self-insured employers to cover the full cost to ensure that the greatest number of people are protected.
Internal Medicine Physician Rahul Deepankar, M.D. and Pediatrician Jane Kapral, M.D. are the two newest team members to join the Riverside Medical Center - West Campus in Coal City.
COVID-19 test results are now being automatically sent to GP systems as well as being communicated to the individual, giving GPs visibility of which of their patients have had COVID-19 tests and whether they have tested positive or negative.
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its supplemental Abbreviated New Drug Application (ANDA) for Phentermine HCl Capsules, 15 mg.
› Verified 9 days ago